<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02225262</url>
  </required_header>
  <id_info>
    <org_study_id>CK Prostate-01</org_study_id>
    <nct_id>NCT02225262</nct_id>
  </id_info>
  <brief_title>A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors</brief_title>
  <official_title>Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating Homogenous Dose Distribution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Community Cancer Center, Normal, Illinois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Community Cancer Center, Normal, Illinois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of CyberKnife radiosurgery in patients&#xD;
      with early stage prostate cancer.&#xD;
&#xD;
      The investigators hypothesize that hypofractionated stereotactic radiotherapy via the&#xD;
      CyberKnife® can deliver tumor ablating doses of radiation to prostate tumors safely and&#xD;
      effectively while sparing the adjacent tissues (rectum, bladder, ureters, urethra, penile&#xD;
      bulb, and bowel) from receiving damaging doses of radiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CyberKnife system is a type of radiation machine that uses a special system to precisely&#xD;
      focus large doses of x-rays (radiation) on the tumor. The device is designed to concentrate&#xD;
      large doses of radiation onto the tumor so that injury from radiation to the nearby normal&#xD;
      tissue will be minimal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control rate</measure>
    <time_frame>5-10 years</time_frame>
    <description>To assess the effects of hypofractionated stereotactic radiosurgery on the long-term local tumor control of prostate cancer (through documentation of the rate of biochemical Disease-Free Survival [bDFS], Phoenix and ASTRO definitions, at 5 and 10 years).&#xD;
To document the rates of acute and late grade 3-5 gastrointestinal and genitourinary toxicity observed during the years following CyberKnife SRS for prostate cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5-10 years</time_frame>
    <description>To measure the following in the study population: rates of local failure, distant failure, disease-free survival, disease-specific survival; quality of life (QOL) in generic and organ-specific domains.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Cancer of the Prostate</condition>
  <condition>Prostate Neoplasm</condition>
  <arm_group>
    <arm_group_label>CyberKnife Radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CyberKnife Radiosurgery</intervention_name>
    <description>36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction</description>
    <arm_group_label>CyberKnife Radiosurgery</arm_group_label>
    <other_name>CyberKnife</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male Age ≥ 21&#xD;
&#xD;
          -  Histologically proven prostate adenocarcinoma&#xD;
&#xD;
          -  Clinical stage T1b-T2b, N0-Nx, M0-Mx (AJCC 6th Edition)&#xD;
&#xD;
          -  PSA ≤ 20 ng/ml&#xD;
&#xD;
          -  Prostate volume ≤ 100 cc&#xD;
&#xD;
        Patients belonging in one of the following risk groups:&#xD;
&#xD;
          -  Low:&#xD;
&#xD;
               -  CS T1b-T2a and Gleason 2-6 and PSA ≤ 10&#xD;
&#xD;
          -  Intermediate:&#xD;
&#xD;
               -  CS T2b and Gleason 2-6 and PSA ≤ 10, OR&#xD;
&#xD;
               -  CS T1b-T2b, and Gleason 2-6 and PSA ≤ 20 ng/ml OR Gleason 7 and PSA ≤ 10 ng/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any histology other than adenocarcinoma&#xD;
&#xD;
          -  Age &lt; 21&#xD;
&#xD;
          -  KPS &lt;= 40 &lt;70&#xD;
&#xD;
          -  ECOG Performance Status ≥ 2&#xD;
&#xD;
          -  Patient weight &gt;350 lbs. (table limitation)&#xD;
&#xD;
          -  Prior XRT to prostate or lower pelvis&#xD;
&#xD;
          -  Prior surgery or cryotherapy to prostate&#xD;
&#xD;
          -  Implanted hardware or other material that would prohibit appropriate treatment&#xD;
             planning or treatment delivery, in the investigator's opinion&#xD;
&#xD;
          -  Chemotherapy for a malignancy in the last 5 years&#xD;
&#xD;
          -  History of an invasive malignancy (other than this prostate cancer, or basal or&#xD;
             squamous skin cancers) in the last 5 years&#xD;
&#xD;
          -  Hormone ablation for 2 months prior to enrollment, or during treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shermian Woodhouse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Community Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Community Cancer Center</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 22, 2014</study_first_submitted>
  <study_first_submitted_qc>August 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2014</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>CyberKnife</keyword>
  <keyword>Stereotactic</keyword>
  <keyword>Radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

